Drugs / Beinaglutide

Trials 3 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 41 trial
Phase 4 NCT05005741 May 2021 → Dec 2023 obesity disorder, type 2 diabetes mellitus Second Xiangya Hospital of Central South University Unknown No outcome recorded
Phase not applicable2 trials
NCT03987308 Jul 2019 → Sep 2025 overdue diabetes mellitus, noninsulin-dependent, 2 Beijing Hospital Recruiting No outcome recorded
NCT03829891 Aug 2018 → Dec 2019 type 2 diabetes mellitus Xijing Hospital Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/31 trial
Phase 2/3 NCT01185119 Comparator Jun → Dec 2010 University of Aarhus Completed No outcome recorded
Phase 41 trial
Phase 4 NCT02333591 Comparator Jul 2016 → Jun 2018 coronary microvascular disorder Mette Zander Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Beinaglutide ClinicalTrials.gov intervention name — accepted as the source's own label NCT03829891
2

NCT05005741

NCT03987308

Known as Glp-1 (7-36) ChEMBL registry synonym — accepted as the source's own label CHEMBL5095267
Known as Glucagon like peptide-i (7-36) ChEMBL registry synonym — accepted as the source's own label CHEMBL5095267
Known as GlucagonLikePeptide-1 (7-36) ClinicalTrials.gov intervention name — accepted as the source's own label NCT02333591
Known as native glp-1 (7-36) ClinicalTrials.gov intervention name — accepted as the source's own label NCT01185119
Action Activate “novel glucagon-like peptide-1 receptor agonists beinaglutide.” PMID 37864379 Oct 2023
Modality Peptide “GLP-1 is a natural peptide hormone” NCT01185119
Modality Protein / enzyme biologic CHEMBL5095267
Route Other “with infusions of placebo or Native GLP-1” NCT01185119